Xintela AB (publ) (XINT.ST)
SEK 0.32
(-0.63%)
SEK 0.32
(-0.63%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 78 Thousand SEK | 0.0% |
| 2022 | - SEK | 0.0% |
| 2021 | - SEK | 0.0% |
| 2020 | - SEK | -100.0% |
| 2019 | 38 Thousand SEK | -97.67% |
| 2018 | 1.62 Million SEK | 81300.0% |
| 2017 | 2000.00 SEK | -33.33% |
| 2016 | 3000.00 SEK | -99.6% |
| 2015 | 757 Thousand SEK | 7448.86% |
| 2014 | 10.02 Thousand SEK | 0.0% |
| 2013 | - SEK | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 299 Thousand SEK | 283.33% |
| 2024 Q2 | 4000.00 SEK | -98.66% |
| 2023 Q1 | - SEK | 0.0% |
| 2023 Q4 | 78 Thousand SEK | 0.0% |
| 2023 FY | 78 Thousand SEK | 0.0% |
| 2023 Q3 | - SEK | 0.0% |
| 2023 Q2 | - SEK | 0.0% |
| 2022 Q4 | - SEK | 0.0% |
| 2022 Q3 | - SEK | 0.0% |
| 2022 Q2 | - SEK | 0.0% |
| 2022 Q1 | - SEK | 0.0% |
| 2022 FY | - SEK | 0.0% |
| 2021 FY | - SEK | 0.0% |
| 2021 Q4 | - SEK | 0.0% |
| 2021 Q1 | - SEK | 0.0% |
| 2021 Q3 | - SEK | 0.0% |
| 2021 Q2 | - SEK | 0.0% |
| 2020 FY | - SEK | -100.0% |
| 2020 Q1 | - SEK | -100.0% |
| 2020 Q3 | - SEK | 0.0% |
| 2020 Q4 | - SEK | 0.0% |
| 2020 Q2 | - SEK | 0.0% |
| 2019 Q4 | 35 Thousand SEK | 1650.0% |
| 2019 Q3 | 2000.00 SEK | 0.0% |
| 2019 Q2 | - SEK | -100.0% |
| 2019 Q1 | 1000.00 SEK | -99.84% |
| 2019 FY | 38 Thousand SEK | -97.67% |
| 2018 FY | 1.62 Million SEK | 81300.0% |
| 2018 Q4 | 616 Thousand SEK | -0.16% |
| 2018 Q3 | 617 Thousand SEK | 0.0% |
| 2018 Q2 | - SEK | -100.0% |
| 2018 Q1 | 395 Thousand SEK | 0.0% |
| 2017 Q4 | - SEK | -100.0% |
| 2017 FY | 2000.00 SEK | -33.33% |
| 2017 Q1 | 1000.00 SEK | 0.0% |
| 2017 Q2 | - SEK | -100.0% |
| 2017 Q3 | 1000.00 SEK | 0.0% |
| 2016 FY | 3000.00 SEK | -99.6% |
| 2016 Q1 | - SEK | -100.0% |
| 2016 Q4 | - SEK | -100.0% |
| 2016 Q3 | 3000.00 SEK | 0.0% |
| 2016 Q2 | - SEK | 0.0% |
| 2015 Q3 | 309 Thousand SEK | 276.83% |
| 2015 Q2 | 82 Thousand SEK | 0.61% |
| 2015 Q1 | 81.5 Thousand SEK | 0.0% |
| 2015 FY | 757 Thousand SEK | 7448.86% |
| 2015 Q4 | 285 Thousand SEK | -7.77% |
| 2014 FY | 10.02 Thousand SEK | 0.0% |
| 2013 FY | - SEK | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 58.1 Million SEK | 99.866% |
| Ziccum AB (publ) | 3.74 Million SEK | 97.918% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| BioArctic AB (publ) | 615.99 Million SEK | 99.987% |
| Sprint Bioscience AB (publ) | 50.48 Million SEK | 99.845% |
| Mendus AB (publ) | 28.48 Million SEK | 99.726% |
| Genovis AB (publ.) | 158.23 Million SEK | 99.951% |
| Intervacc AB (publ) | 8.01 Million SEK | 99.027% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 4.37 Million SEK | 98.217% |
| Active Biotech AB (publ) | - SEK | -Infinity% |
| Magle Chemoswed Holding AB (publ) | 170.44 Million SEK | 99.954% |
| Bio-Works Technologies AB (publ) | 43.89 Million SEK | 99.822% |
| Aptahem AB (publ) | 2.63 Million SEK | 97.035% |
| Vicore Pharma Holding AB (publ) | - SEK | -Infinity% |
| Kancera AB (publ) | 1.03 Million SEK | 92.464% |
| Infant Bacterial Therapeutics AB (publ) | 77 Thousand SEK | -1.299% |
| Fluicell AB (publ) | 3.33 Million SEK | 97.663% |
| Saniona AB (publ) | 16.84 Million SEK | 99.537% |
| Lipigon Pharmaceuticals AB (publ) | 16.4 Million SEK | 99.525% |
| Biovica International AB (publ) | 7.29 Million SEK | 98.93% |
| Spago Nanomedical AB (publ) | 1.2 Million SEK | 93.516% |
| AcouSort AB (publ) | 10.55 Million SEK | 99.261% |
| Abliva AB (publ) | 137 Thousand SEK | 43.066% |
| Egetis Therapeutics AB (publ) | 57.6 Million SEK | 99.865% |
| Karolinska Development AB (publ) | 2.01 Million SEK | 96.127% |
| OncoZenge AB (publ) | 3000.00 SEK | -2500.0% |
| Amniotics AB (publ) | - SEK | -Infinity% |
| 2cureX AB (publ) | 155 Thousand SEK | 49.677% |
| CombiGene AB (publ) | 5.54 Million SEK | 98.593% |
| Asarina Pharma AB (publ) | - SEK | -Infinity% |
| Calliditas Therapeutics AB (publ) | 1.2 Billion SEK | 99.994% |
| Camurus AB (publ) | 1.71 Billion SEK | 99.995% |
| Corline Biomedical AB | 25.03 Million SEK | 99.688% |
| IRLAB Therapeutics AB (publ) | 5.67 Million SEK | 98.626% |
| Isofol Medical AB (publ) | 721 Thousand SEK | 89.182% |
| I-Tech AB | 120.86 Million SEK | 99.935% |
| Hansa Biopharma AB (publ) | 134.09 Million SEK | 99.942% |
| Cyxone AB (publ) | 5.14 Million SEK | 98.485% |
| ExpreS2ion Biotech Holding AB (publ) | 7.05 Million SEK | 98.894% |
| Biosergen AB | - SEK | -Infinity% |
| Cantargia AB (publ) | - SEK | -Infinity% |
| NextCell Pharma AB | 10.66 Million SEK | 99.269% |
| Xspray Pharma AB (publ) | - SEK | -Infinity% |
| Elicera Therapeutics AB (publ) | 11.23 Million SEK | 99.305% |
| Nanologica AB (publ) | 1.44 Million SEK | 94.595% |
| SynAct Pharma AB | - SEK | -Infinity% |
| Annexin Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| Stayble Therapeutics AB (publ) | - SEK | -Infinity% |
| LIDDS AB (publ) | - SEK | -Infinity% |
| Lipum AB (publ) | 53 Thousand SEK | -47.17% |
| BioInvent International AB (publ) | 71.46 Million SEK | 99.891% |
| Alzinova AB (publ) | 270 Thousand SEK | 71.111% |
| Oncopeptides AB (publ) | 35.22 Million SEK | 99.779% |
| Pila Pharma AB (publ) | 1.46 Million SEK | 94.669% |
| Guard Therapeutics International AB (publ) | - SEK | -Infinity% |
| Scandinavian ChemoTech AB (publ) | 2.82 Million SEK | 97.236% |
| Simris Alg AB (publ) | 4.35 Million SEK | 98.209% |
| Diamyd Medical AB (publ) | 130 Thousand SEK | 40.0% |
| Xbrane Biopharma AB (publ) | 238.72 Million SEK | 99.967% |
| Ascelia Pharma AB (publ) | - SEK | -Infinity% |
| Diagonal Bio AB (publ) | 23 Thousand SEK | -239.13% |